Epidemiology and prevention of HPV-driven cervical cancer in urban-rural China: a population-based study of 60,280 women.

  • Post category:Gynecologic Cancer
  • Reading time:1 min read

Journal: Scientific reports

This cross-sectional study evaluated HPV epidemiology and screening performance in Putian, a southeastern region of China, using data from 60,280 women aged 35–64 years who participated in a free cervical cancer screening program between 2021 and 2023.

Key findings:

  • Overall HPV prevalence: 9.27% (95% CI: 9.04–9.50).
  • Most common high-risk genotypes:
    • HPV 52: 35.61% of infections
    • HPV 58: 16.56%
    • HPV 16: 12.38%
  • Cervical cancer incidence:
    • Peak in women 55–59 years: 95/100,000
    • Secondary peak in 50–54 years: 89/100,000
    • Notable early-onset increase in 40–44 years: 46/100,000
    • National average incidence: 56/100,000
  • HPV 16/18 were responsible for most cervical cancer cases, with HPV 58, 33, and 52 as important additional high‑risk genotypes.
  • ThinPrep cytology (TCT) showed both clinically meaningful underdiagnosis and overdiagnosis, indicating limitations as a standalone strategy.
  • Self-sampling/self-screening: only 1.33% of women engaged in self-sampling/self-screening.
  • Urban–rural differences: persistent disparities were observed, particularly in HPV 52/58/33 prevalence and screening participation.

Implications:

  • Vaccination: the genotype distribution (high burden of 52/58/33) supports prioritizing broader-coverage vaccination, especially 9‑valent HPV vaccines, in this region.
  • Screening and triage: low participation and TCT performance issues argue for improved screening approaches and triage, including consideration of methylation-based testing and targeted efforts to address urban–rural disparities.

Leave a Reply